Definium Therapeutics, Inc.
- DFTX
- NASDAQ
- Biotechnology
- Neurology (CNS)
- Clinical-Stage Biopharma
$32.97
Today +2.71%Quote Oct 19, 2026, 08:00 PM UTC
−15.05%over the last month
Max drawdown −20.4%From 1-month high −18.2%3 months −26.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Definium Therapeutics
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD).
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
106
Market value
$4.43B
Quote Oct 19
Floor
$30.65
7.0% below price
Resistance
$33.47
1.5% above price
Price vs analyst targets
12 analysts
Lowest target
$52.00Highest target
$79.00
$52.00Highest target
$79.00
- Price $32.97
- Average target $67.45
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 105% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about DFTXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free